SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006687
Filing Date
2021-05-10
Accepted
2021-05-10 16:31:20
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20210331x10q.htm   iXBRL 10-Q 1433232
2 EX-31.1 sgtx-20210331ex3110efe69.htm EX-31.1 24537
3 EX-31.2 sgtx-20210331ex31236b807.htm EX-31.2 25748
4 EX-32.1 sgtx-20210331ex32115ed18.htm EX-32.1 11448
  Complete submission text file 0001558370-21-006687.txt   4900382

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20210331.xsd EX-101.SCH 36253
6 EX-101.CAL sgtx-20210331_cal.xml EX-101.CAL 38261
7 EX-101.DEF sgtx-20210331_def.xml EX-101.DEF 106995
8 EX-101.LAB sgtx-20210331_lab.xml EX-101.LAB 361531
9 EX-101.PRE sgtx-20210331_pre.xml EX-101.PRE 256228
10 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20210331x10q_htm.xml XML 585898
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 21907712
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences